Kaken Pharmaceutical Co (TSE:4521) EBIT per Share : 円617.74 (TTM As of Sep. 2024)

View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co EBIT per Share?

Kaken Pharmaceutical Co's EBIT per Share for the three months ended in Sep. 2024 was 円445.49. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was 円617.74.

During the past 12 months, the average EBIT per Share Growth Rate of Kaken Pharmaceutical Co was 341.10% per year. During the past 3 years, the average EBIT per Share Growth Rate was -18.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was -20.40% per year. During the past 10 years, the average EBIT per Share Growth Rate was -7.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Kaken Pharmaceutical Co's EBIT per Share or its related term are showing as below:

TSE:4521' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -32 Med: 5.5 Max: 36.2
Current: -18.2

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Kaken Pharmaceutical Co was 36.20% per year. The lowest was -32.00% per year. And the median was 5.50% per year.

TSE:4521's 3-Year EBIT Growth Rate is ranked worse than
82.18% of 836 companies
in the Drug Manufacturers industry
Industry Median: 6.8 vs TSE:4521: -18.20

Kaken Pharmaceutical Co's EBIT for the three months ended in Sep. 2024 was 円16,871 Mil.

Kaken Pharmaceutical Co EBIT per Share Historical Data

The historical data trend for Kaken Pharmaceutical Co's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co EBIT per Share Chart

Kaken Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT per Share

Get a 7-Day Free Trial

679.84

483.91

366.05

181.90

260.04

Kaken Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															58.59	94.19	15.32	62.75	445.49

Kaken Pharmaceutical Co EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Kaken Pharmaceutical Co's EBIT per Share for the fiscal year that ended in Mar. 2024 is calculated as

	EBIT per Share		(A: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	9813	/	37.737
=	260.04

Kaken Pharmaceutical Co's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	16871	/	37.871
=	445.49

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円617.74

Kaken Pharmaceutical Co (TSE:4521) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Kaken Pharmaceutical Co EBIT per Share Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Kaken Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

KKPCF:USA

Address

28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650

Website

http://www.kaken.co.jp

Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co Headlines

No Headlines